McLaurin, Kristen A.
Li, Hailong
Khalili, Kamel
Mactutus, Charles F.
Booze, Rosemarie M.
Funding for this research was provided by:
National Institute on Drug Abuse (DA059310, DA056288)
National Institute of Mental Health (MH106392)
National Institute of Neurological Disorders and Stroke (NS100624)
Article History
Received: 15 August 2023
Revised: 23 January 2024
Accepted: 24 January 2024
First Online: 14 February 2024
Declarations
:
: K.K. is named as an inventor on patents that cover the viral gene editing technology that is the subject of this article. In addition, K.K. is a co-founder, board member (observer), and chief scientific adviser and holds equity in Excision Biotherapeutics, a biotech startup that has licensed the viral gene editing technology from Temple University for commercial development and clinical trials. All other authors have no interests to disclose.